Accessibility Menu
Jazz Pharmaceuticals Plc logo

Jazz Pharmaceuticals Plc

(NASDAQ) JAZZ

Current Price$181.83
Market Cap$11.19B
Since IPO (2007)+925%
5 Year+5%
1 Year+28%
1 Month+8%

Jazz Pharmaceuticals Plc Financials at a Glance

Market Cap

$11.19B

Revenue (TTM)

$4.27B

Net Income (TTM)

$356.15M

EPS (TTM)

$-5.97

P/E Ratio

-30.45

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$181.83

Volume

183.5

Open

$180.72

Previous Close

$181.80

Daily Range

$178.40 - $183.51

52-Week Range

$95.49 - $198.00

JAZZ: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jazz Pharmaceuticals Plc

Industry

Pharmaceuticals

Employees

2,890

CEO

Renée D. Galá, MBA

Headquarters

Dublin, 4, IE

JAZZ Financials

Key Financial Metrics (TTM)

Gross Margin

88%

Operating Margin

5%

Net Income Margin

-8%

Return on Equity

-8%

Return on Capital

2%

Return on Assets

-3%

Earnings Yield

-3.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.19B

Shares Outstanding

61.56M

Volume

183.5

Short Interest

0.00%

Avg. Volume

984.61K

Financials (TTM)

Gross Profit

$3.76B

Operating Income

$224.42M

EBITDA

$108.46M

Operating Cash Flow

$1.36B

Capital Expenditure

$58.75M

Free Cash Flow

$1.30B

Cash & ST Invst.

$2.44B

Total Debt

$5.42B

Jazz Pharmaceuticals Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.20B

+10.1%

Gross Profit

$1.17B

+22.3%

Gross Margin

97.94%

N/A

Market Cap

$11.19B

N/A

Market Cap/Employee

$4.00M

N/A

Employees

2,800

N/A

Net Income

$203.45M

+6.5%

EBITDA

$278.56M

-29.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$2.97B

+6.4%

Accounts Receivable

$830.75M

+15.9%

Inventory

$416.96M

-13.2%

Long Term Debt

$4.38B

-28.4%

Short Term Debt

$1.03B

+2149.7%

Return on Assets

-3.05%

N/A

Return on Invested Capital

2.38%

N/A

Free Cash Flow

$296.79M

-23.0%

Operating Cash Flow

$362.52M

-9.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDGLMadrigal Pharmaceuticals, Inc.
$454.22+2.76%
AXSMAxsome Therapeutics, Inc.
$158.88+0.64%
ABVXAbivax S.A.
$123.03-0.78%
CYTKCytokinetics, Incorporated
$62.95+1.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$45.69-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.97-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$75.91+0.01%
IBITiShares Bitcoin Trust
$39.82-0.01%

Questions About JAZZ

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.